Gene therapy with standard treatment for high-risk prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial combines gene therapy with hormone therapy, radiation, and possibly surgery to treat high-risk prostate cancer. It aims to improve outcomes by adding gene therapy to standard treatments and will require additional biopsies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have prostate cancer confirmed by a biopsy.
- Your cancer must be high-risk, meaning you have one or more of these: PSA > 20, a Gleason score of 8 to 10, a primary Gleason pattern of 5, more than 4 biopsy cores with Gleason 8-10, or clinical stage T3a-T4.
- You cannot have had prior prostate cancer treatment like surgery, radiation, or hormone therapy.
- You must be in good physical condition (ECOG performance status 0 or 1) and have adequate organ function.
- Your cancer must not have spread to distant organs (except maybe local lymph nodes) and you must not have had other cancers recently except certain skin cancers.
- You must be willing to provide biopsies and comply with the study protocol.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different drugs before prostate surgery based on a person's genetic profile. It aims to find better treatments for high-risk prostate cancer that hasn't spread yet.
This trial tests an experimental vaccine (2141-V11) combined with standard hormone therapy and an anti-androgen drug before prostate removal surgery. It aims to see if the combination can help the immune system fight the cancer more effectively.
This trial uses genetic test results from your prostate cancer to guide treatment choices. It may help find therapies that better match the specific gene changes in your cancer.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This study tests a combination of hormone therapy and a targeted drug before prostate surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach can improve outcomes.
This study looks at combining stereotactic body radiation therapy (a precise type of radiation) with hormone therapy for men with high-risk prostate cancer that hasn't spread. The goal is to see how well this treatment works with fewer side effects.
Hear when a new High Risk Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.